Brown E J, Joiner K A, Frank M M
J Clin Invest. 1983 Jun;71(6):1710-9. doi: 10.1172/jci110925.
We examined the fate of desialated autologous erythrocytes injected intravenously into guinea pigs (GP). Desialated GP erythrocytes (E) were lysed directly or cleared by the reticuloendothelial system in normal GP (NIH-GP) and cleared by the reticuloendothelial system in GP genetically deficient in the classical complement pathway component C4 (C4D-GP), which activate complement only via the alternative pathway. Desialated E were also cleared in cobra venom factor-treated GP (CVF-GP), which had less than 1% of normal C3 levels, but were not cleared at all in C4D-CVF-GP. Preinjection of asialoorosomucoid (ASOR) and ovalbumin (OVA) had no effect on the rate of E clearance. These in vivo studies indicated that complement activation is essential for clearance of desialated E and that clearance is unaffected by blockade of galactose or mannose receptors. Inhibition of complement-mediated clearance required blockade of both classical and alternative complement pathways. In vitro studies showed that lysis of desialated E could occur in NIH-GP serum (GPS) but not in C4D-GPS. Surprisingly, CVF-GPS also caused lysis of desialated E. Lysis was dependent on both natural antibody to desialated E and classical pathway activation; natural antibody was of both the IgG and IgM classes. C3 uptake studies demonstrated that almost 10 times as many C3 molecules/E were deposited by NIH-GPS as by C4D-GPS or CVF-GPS onto desialated E. Approximately equal numbers of C3 molecules were deposited by CVF-GPS, which did lyse desialated E, and by C4D-GPS, which did not. We suggest that the molecular mechanism of in vivo clearance and in vitro lysis of desialated E by CVF-GP is via classical pathway deposition of C3b into sites on the erythrocyte surface protected from inactivation by H (beta 1H) and I (C4b/3b inactivator). Deposition of C3b into these sites by alternative pathway activation is sufficient to cause clearance but not lysis of desialated E. CVF-GPS may not represent an adequate reagent for testing the complement dependence of various biologic phenomena, particularly if the question involves surfaces that can provide protected sites for C3b molecules.
我们研究了静脉注射到豚鼠(GP)体内的去唾液酸自体红细胞的命运。去唾液酸的GP红细胞(E)在正常GP(NIH - GP)中直接裂解或被网状内皮系统清除,在经典补体途径成分C4基因缺陷的GP(C4D - GP)中被网状内皮系统清除,后者仅通过替代途径激活补体。去唾液酸的E在眼镜蛇毒因子处理的GP(CVF - GP)中也被清除,其C3水平不到正常水平的1%,但在C4D - CVF - GP中根本不被清除。注射去唾液酸血清类黏蛋白(ASOR)和卵清蛋白(OVA)对E的清除率没有影响。这些体内研究表明,补体激活对于去唾液酸E的清除至关重要,并且清除不受半乳糖或甘露糖受体阻断的影响。抑制补体介导的清除需要同时阻断经典和替代补体途径。体外研究表明,去唾液酸的E在NIH - GP血清(GPS)中可发生裂解,但在C4D - GPS中则不会。令人惊讶的是,CVF - GPS也会导致去唾液酸的E裂解。裂解既依赖于针对去唾液酸E的天然抗体,也依赖于经典途径的激活;天然抗体包括IgG和IgM两类。C3摄取研究表明,NIH - GPS沉积在去唾液酸E上的C3分子数量/E几乎是C4D - GPS或CVF - GPS的10倍。能够裂解去唾液酸E的CVF - GPS和不能裂解的C4D - GPS沉积的C3分子数量大致相等。我们认为,CVF - GP对去唾液酸E进行体内清除和体外裂解的分子机制是通过C3b经经典途径沉积到红细胞表面免受H(β1H)和I(C4b/3b灭活剂)灭活的位点上。通过替代途径激活将C3b沉积到这些位点足以导致去唾液酸E的清除,但不会导致其裂解。CVF - GPS可能不是用于测试各种生物学现象对补体依赖性的合适试剂,特别是如果问题涉及能够为C3b分子提供受保护位点的表面时。